Welcome to SynapCell

SynapCell is a biotechnology company providing the CNS drug manufacturing industry with translational drug discovery solutions to reveal the therapeutic potential of their molecules targeting CNS disorders.

Services

synapcell_MTLE_mouse_in-vivo

Epilepsy solutions

Since 2005 SynapCell has been assessing the efficacy of your drug candidates for epilepsy using surface and deep EEG recording. We use a translational approach combining relevant animal models of different types of epilepsy, protocols performed in clinical conditions, and quantitative results to reveal brain dysfunction and epileptic seizures.

synapcell_cns_drug_discovery

Solutions for other CNS disorders

With a translational approach combining relevant animal models of CNS disorders, protocols performed in clinical conditions and EEG-related technologies to reveal brain activities, SynapCell assesses the effects of your drug candidates in the treatment of CNS disorders with unmet needs.

synapcell_eeg_phenotyping

EEG phenotyping of rodent models

Develop your personalized drug discovery tool using SynapCell’s expertise in the EEG phenotyping of rodent models to improve your insights into the relevance of your therapeutic targets in CNS disorders.

What's new

Epilepsy: pitolisant’s promising early Phase II study confirms the interest of SynapCell’s approach to AED discovery

The recent clinical data obtained with a new antiepileptic drug (AED) candidate called pitolisant, developed by Bioprojet, in an early Phase II study [1] confirms the interest in SynapCell’s strategic approach, associating animal models and EEG, as a translational marker of brain’s function. Moreover, it validates the relevance of our animal models for drug discovery in Epilepsy, GAERS and MTLE mouse.

[1] Efficacy of the histamine 3 receptor (H3R) antagonist pitolisant (formerly known as tiprolisant; BF2.649) in epilepsy: dose-dependent effects in the human photosensitivity model Kasteleijn-Nolst Trenité D. et al. Epilepsy Behav, 2013

see more…